Abstract
A population-based budget impact analysis (BIA) was developed to inform health care decision makers. This analysis estimated the budgetary impact of adding ponesimod to a formulary list by assessing the drug acquisition and administration costs of all disease modifying treatments (DMTs) for relapsing multiple sclerosis (RMS) currently on the market.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
